(Q44056454)

29 November 2017

title

Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism (English)

1 reference

29 November 2017

Skott P

1

1 reference

29 November 2017

Lucht E

series ordinal

2

1 reference

29 November 2017

Ehnlund M

series ordinal

3

1 reference

29 November 2017

Björling E

series ordinal

4

1 reference

29 November 2017

publication date

1 May 2002

1 reference

29 November 2017

1 reference

29 November 2017

volume

8

1 reference

29 November 2017

issue

3

1 reference

29 November 2017

page(s)

160-167

1 reference

A new classification for HIV-1

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Secretory leukocyte protease inhibitor inhibits infection of monocytes and lymphocytes with human immunodeficiency virus type 1 but does not interfere with transcytosis of cell-associated virus across tight epithelial barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Neutralization of rotavirus and recognition of immunologically important epitopes on VP4 and VP7 by human IgA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

New procedures for preparation and isolation of conjugates of proteins and a synthetic copolymer of D-amino acids and immunochemical characterization of such conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Human Submandibular Saliva Aggregates HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Human Submandibular Saliva Specifically Inhibits HIV Type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Endogenous mucosal antiviral factors of the oral cavity

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Endogenous salivary inhibitors of human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Human immunodeficiency virus type 1 p24 production and antigenic variation in tissue culture of isolates with various growth characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Coreceptor-dependent inhibition of the cell fusion activity of simian immunodeficiency virus Env proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Functions of the N-terminal domain of secretory leukoprotease inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Simplified procedure for carrying out simultaneous multiple hydrogen fluoride cleavages of protected peptide resins

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Secretory leukocyte proteinase inhibitor is a major leukocyte elastase inhibitor in human neutrophils

1 reference

https://api.crossref.org/works/10.1034%2FJ.1601-0825.2002.01807.X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1034/J.1601-0825.2002.01807.X

1 reference

29 November 2017

1 reference